Would transplanting kidneys currently being discarded in the US place programs at risk for regulatory review?

Jon J. Snyder, PhD Director of Transplant Epidemiology Scientific Registry of Transplant Recipients Minneapolis Medical Research Foundation Minneapolis, Minnesota, USA



Disclosures


Jon J. Snyder, PhD Director of Transplant Epidemiology Scientific Registry of Transplant Recipients Minneapolis Medical Research Foundation Minneapolis, MN, USA


I have no financial relationships to disclose within the past 12 months relevant to my presentation. The ACCME defines 'relevant' financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

My presentation does/does not include discussion of off-label or investigational use. I do/do not intend to reference unlabeled/unapproved uses of drugs or products in my presentation.


This work was supported wholly or in part by HRSA contract HHSH-250-2015-00009C. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of HHS, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.








KDRI distribution for not recovered, discarded, and transplanted kidneys



Disposition by KDRI




SCIENTIFIC REGISTRY O

Factors included in the current deceased donor kidney risk adjustment models

Candidate/Recipient Factors:	
•Any previous malignancy	
Diabetes	
• Ethnicity	
•Highest education level	
•Race	
•Symptomatic peripheral vascular disease	
•Total serum albumin (g/dL)	
•Age at transplant (years)	
•BMI (kg/m2, calculated from height and weight)	
•HBV core antibody	
•HCV serostatus	
• HIV serostatus	
•Most recent CPRA (%)	
Previous solid organ transplant	
• Primary diagnosis	
Primary source of payment	
•Procedure type	
•Total cold ischemia time (hours)	
 Total ESRD time at transplant (days) 	




How good is the model at adjusting for donor risk?



Snyder JJ, Salkowski N, Wey A, et. al., Effects of High-Risk Kidneys on Scientific Registry of Transplant Recipients Program Quality Reports. Am J Transplant, 2016. In Press.

TRANSPLANT RECIPIEN

Do programs with high percentages of high-risk donors have worse outcomes evaluations?



Snyder JJ, Salkowski N, Wey A, et. al., Effects of High-Risk Kidneys on Scientific Registry of Transplant Recipients Program Quality Reports. Am J Transplant, 2016. In Press.



How would a carve-out of high risk kidneys change current evaluations?

Population Evaluated	Programs Flagged by MPSC
All transplants (standard PSR methodology)	30
Low-risk* donor transplants alone	31
All transplants + (low- or high-risk donor alone)	30
All transplants + low-risk donor transplants alone	25


*Low risk = KDPI <85%; high risk = KDPI \geq 85%

What if kidneys currently discarded or not recovered were transplanted?

- Matching analysis population: donors from January 1, 2012–June 30, 2014.
- 3,090 not recovered kidneys and 6,726 discarded kidneys matched to transplanted kidneys by KDPI and donor age.
- Outcome of hypothetical transplant assumed to be the same as the matched transplant.
- Programs were allocated discarded/not-recovered kidneys in 1 of 2 ways:
 - Proportional to the program's historic use of high-risk kidneys.
 - Proportional to the program's total number of transplants performed.




Matching analysis: If not recovered or discarded kidneys were used, observed and expected continue to align well.






Correlation among program evaluations with and without the hypothetical transplants: 0.98



Common Questions:

Question: Risk adjustment models have poor discrimination, i.e., low C statistics. Doesn't this call into question the ability to judge programs?

 Discrimination assesses how well the models can distinguish two patients. Model calibration describes how well the models predict absolute risk, which is fairly robust. Models are used to provide aggregate program evaluations based on expected outcomes (calibration) for all patients at the program, not to distinguish any two patients (discrimination).



Common Questions:

Question: What about important risk factors that are not included in the risk adjustment models?

• SRTR supports all efforts to collect necessary risk factors to better calibrate risk adjustment models. Cornfield's Theorem allows one to assess potential bias introduced by unmeasured risk factors. For example, if a risk factor exists that confers an additional 25% increased risk (and isn't correlated with factors already in the model), and 10% of your recipients have it, and no other programs in the country perform any of these transplants, program hazard ratios may be biased by 0.02, i.e., from 1.00 to 1.02.



Summary:

- This analysis demonstrates a few key findings:
 - Discarded and non-recovered kidneys have KDPI largely within the range of kidneys that were transplanted.
 - Risk adjustment models are well calibrated for donor risk factors.
 - Carving out high-risk kidneys from evaluations has little effect on which programs are identified as underperforming.
 - Transplanting kidneys currently discarded would have little/no impact on program evaluations, under the assumption that they would be transplanted into similar candidates by programs that achieve similar outcomes. If this assumption is violated, the "KDPI" effect in the models will recalibrate to take this into account during each evaluation cycle.



Conclusions:

- Avoidance of risk based on measured and risk-adjusted factors, e.g., KDPI, is unwarranted.
- Important factors missed by current OPTN data collection should be collected to better calibrate the risk adjustment models and to assure care teams that appropriate medical care can be provided to patients without fear of impacting outcomes assessments.



Acknowledgments

Co-Authors: Nicholas Salkowski, PhD Bryn Thompson, MPH Andrew Wey, PhD Ajay Israni, MD, MS Bertram Kasiske, MD, FACP

HRSA Division of Transplantation: Monica Lin, PhD



Would transplanting kidneys currently being discarded in the US place programs at risk for regulatory review?

Jon J. Snyder, PhD Director of Transplant Epidemiology Scientific Registry of Transplant Recipients Minneapolis Medical Research Foundation Minneapolis, Minnesota, USA

